FDA ties a death to burst balloons on the Edwards SAPIEN M3 delivery system

MedDevice Startups Staff · 6 days ago · 2 min read · Via Medical Device Network

FDA issued an early alert on October 15 covering the Commander M delivery system, the catheter that carries the Edwards SAPIEN M3 valve across the septum and into the mitral position. Edwards has received three reports of the balloon bursting during inflation. One patient died and another had a serious injury.

Edwards told customers to stop using the affected lots immediately. A burst balloon can release fragments into the circulation, or leave the device impossible to withdraw through the guide sheath, which turns the case into open surgery. These patients were routed to a transcatheter valve because they were poor surgical candidates, so the fallback carries its own risk of death.

FDA approved SAPIEN M3 on December 23, 2025, the first transseptal transcatheter therapy for mitral regurgitation to clear the agency. The alert reflects reports through October 5, which puts a delivery system failure inside the first ten months of commercial use. Early alerts exist to move a signal like this before a recall gets classified.

Questions & Answers

What did the FDA early alert say about the Edwards SAPIEN M3 delivery system?

FDA issued an early alert on October 15, 2026 covering the Commander M delivery system used to implant the Edwards SAPIEN M3 mitral valve. Edwards reported three cases of the balloon bursting during inflation, including one death and one serious injury, and told customers to stop using the affected lots.

When did FDA approve the Edwards SAPIEN M3 mitral valve system?

FDA approved the Edwards SAPIEN M3 system on December 23, 2025. It was the first transseptal transcatheter therapy approved in the United States for mitral regurgitation.

What harm can a burst balloon on the Edwards Commander M delivery system cause?

Edwards says a burst balloon can send fragments into the circulation or leave the device impossible to retrieve through the guide sheath. Retrieval can then require surgery, which carries high risk because SAPIEN M3 patients are generally poor surgical candidates.

← Back to Regulatory